Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Cash from Financing Activities (2019 - 2025)

aTYR PHARMA's Cash from Financing Activities history spans 7 years, with the latest figure at -$131000.0 for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 100.7% year-over-year to -$131000.0; the TTM value through Dec 2025 reached $66.0 million, up 65.59%, while the annual FY2025 figure was $66.0 million, 65.59% up from the prior year.
  • Cash from Financing Activities reached -$131000.0 in Q4 2025 per ATYR's latest filing, down from $29.6 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $83.9 million in Q3 2021 to a low of -$131000.0 in Q4 2025.
  • Average Cash from Financing Activities over 5 years is $14.4 million, with a median of $6.9 million recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: tumbled 103.91% in 2024, then skyrocketed 28306.67% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $28000.0 in 2021, then surged by 3178.57% to $918000.0 in 2022, then soared by 557.3% to $6.0 million in 2023, then surged by 212.21% to $18.8 million in 2024, then plummeted by 100.7% to -$131000.0 in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Cash from Financing Activities are -$131000.0 (Q4 2025), $29.6 million (Q3 2025), and $17.9 million (Q2 2025).